A systematic evaluation of the potential of PCTA-NCS ligand as a bifunctional chelating agent for design of 177Lu radiopharmaceuticals
Usha Pandey(Bhabha Atomic Research Centre), Ashutosh Dash(Bhabha Atomic Research Centre), Naresh Gamre(Bhabha Atomic Research Centre), Haladhar Dev Sarma(Bhabha Atomic Research Centre), Yogendra Kumar(Bhabha Atomic Research Centre), Priyalatha Shetty(Bhabha Atomic Research Centre)
Cited by 16
Related Papers
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
|Nuclear Medicine and Molecular Imaging|2015|375
Sustained Availability of <sup>99m</sup>Tc: Possible Paths Forward
|Journal of Nuclear Medicine|2012|140
Peptide Receptor Radionuclide Therapy: An Overview
|Cancer Biotherapy and Radiopharmaceuticals|2015|122
Targeted Radionuclide Therapy - An Overview
|Current Radiopharmaceuticals|2013|117
Development of an electrochemical 90Sr–90Y generator for separation of 90Y suitable for targeted therapy
|Nuclear Medicine and Biology|2008|99